BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23834817)

  • 1. Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect.
    Mathijssen NC; Masereeuw R; Holme PA; van Kraaij MG; Laros-van Gorkom BA; Peyvandi F; van Heerde WL
    Thromb Res; 2013 Aug; 132(2):256-62. PubMed ID: 23834817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patients.
    van Geffen M; Mathijssen NC; Holme PA; Laros-van Gorkom BA; van Kraaij MG; Masereeuw R; Peyvandi F; van Heerde WL
    Thromb Res; 2013 Jul; 132(1):116-22. PubMed ID: 23731565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency.
    Gorkom BL; Holme PA; Joch C; Rogosch T; Feussner A; McKeand W; Roberts J; van Heerde W
    Hematology; 2020 Dec; 25(1):17-25. PubMed ID: 31852380
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of coagulant activity of factor VII and activated factor VII activity assays when used for determination of recombinant activated factor VII levels in plasma.
    Scharling B; Nielsen GG; Klitgaard T; Skovsted TA; Møss J; Segel S; Larsen LF
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):677-84. PubMed ID: 17890956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic effect of recombinant factor VIIa in factor VII deficient patients.
    Mathijssen NC; Masereeuw R; Verbeek K; Lavergne JM; Costa JM; van Heerde WL; Nováková IR
    Br J Haematol; 2004 May; 125(4):494-9. PubMed ID: 15142120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII.
    Schulman S; Tjønnfjord GE; Wallensten R; Martinowitz U; Kenet G
    Thromb Haemost; 2005 Dec; 94(6):1177-80. PubMed ID: 16411390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency.
    Berrettini M; Mariani G; Schiavoni M; Rocino A; Di Paolantonio T; Longo G; Morfini M
    Haematologica; 2001 Jun; 86(6):640-5. PubMed ID: 11418374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison between recombinant activated factor VII (Aryoseven) and Novoseven in patients with congenital factor VII deficiency.
    Faranoush M; Abolghasemi H; Toogeh G; Karimi M; Eshghi P; Managhchi M; Hoorfar H; Dehdezi BK; Mehrvar A; Khoeiny B; Kamyar K; Heshmat R; Baghaeipour MR; Mirbehbahani NB; Fayazfar R; Ahmadinejad M; Naderi M
    Clin Appl Thromb Hemost; 2015 Nov; 21(8):724-8. PubMed ID: 24651301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of factor VII-deficient patients undergoing joint surgeries--preliminary results of locally developed treatment regimen.
    Windyga J; Zbikowski P; Ambroziak P; Baran B; Kotela I; Stefanska-Windyga E
    Haemophilia; 2013 Jan; 19(1):89-93. PubMed ID: 22845882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of recombinant factor VIIa in the rat--a comparison of bio-, immuno- and isotope assays.
    Thomsen MK; Diness V; Nilsson P; Rasmussen SN; Taylor T; Hedner U
    Thromb Haemost; 1993 Sep; 70(3):458-64. PubMed ID: 8259549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect.
    Morfini M; Batorova A; Mariani G; Auerswald G; Bernardi F; Di Minno G; Dolce A; Fede C; Giansily-Blaizot M; Ingerslev J; Martinowitz U; Napolitano M; Pinotti M; Schved JF;
    Thromb Haemost; 2014 Aug; 112(2):424-5. PubMed ID: 24763923
    [No Abstract]   [Full Text] [Related]  

  • 12. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience.
    Nicolaisen EM
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S119-23. PubMed ID: 9819042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prophylactic use of a recombinant activated factor VII in delivery haemorrhage by caesarean in a woman with major factor VII deficiency: a case report].
    Comes JF; Devignes J; Thiebaugeorges O; Briquel ME; Lecompte T
    Ann Biol Clin (Paris); 2011; 69(6):713-9. PubMed ID: 22123573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
    Lindley CM; Sawyer WT; Macik BG; Lusher J; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
    Clin Pharmacol Ther; 1994 Jun; 55(6):638-48. PubMed ID: 8004880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A.
    Villar A; Aronis S; Morfini M; Santagostino E; Auerswald G; Thomsen HF; Erhardtsen E; Giangrande PL
    Haemophilia; 2004 Jul; 10(4):352-9. PubMed ID: 15230949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency.
    Huang WY; Kruskall MS; Bauer KA; Uhl L; Shaz BH
    Transfusion; 2004 Nov; 44(11):1562-6. PubMed ID: 15504160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated recombinant activated factor VII administration in a patient with congenital factor VII deficiency undergoing modified radical hysterectomy: a case report.
    Shirasawa H; Yoshioka T; Sawada K; Terada Y
    Haemophilia; 2014 Jan; 20(1):e101-3. PubMed ID: 24261688
    [No Abstract]   [Full Text] [Related]  

  • 18. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation.
    Mariani G; Napolitano M; Dolce A; Pérez Garrido R; Batorova A; Karimi M; Platokouki H; Auerswald G; Bertrand AM; Di Minno G; Schved JF; Bjerre J; Ingerslev J; Sørensen B; Ruiz-Saez A; ;
    Thromb Haemost; 2013 Feb; 109(2):238-47. PubMed ID: 23238632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding.
    Smith MP; Ludlam CA; Collins PW; Hay CR; Wilde JT; Grigeri A; Melsen T; Savidge GF
    Thromb Haemost; 2001 Oct; 86(4):949-53. PubMed ID: 11686351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.